Zejing Wang, MD/PhD
Pfizer
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Zejing Wang, MD/PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:28 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07566156 · Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)Astellas Pharma Global Development, Inc. · recruiting · Urothelial Cancer, Urinary Bladder Neoplasms · study director
- Ph3NCT04223856 · Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerAstellas Pharma Global Development, Inc. · active not recruiting · Urothelial Cancer
- Ph1/Ph2NCT03310957 · Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerSeagen Inc. · completed · Triple Negative Breast Neoplasms
- Ph1NCT01969643 · A Safety Study of SGN-LIV1A in Breast Cancer PatientsSeagen Inc. · completed · HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.